Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

On the same day North Carolina hospitals reported a record number of COVID-19 patients in intensive care units across the state, Gov. Roy Cooper signaled he will take action expanding access to a ...

The US Food and Drug Administration said Monday it had issued an emergency use authorization for Eli Lilly and Co's monoclonal antibody therapy to treat mild to moderate coronavirus infections in ...

While doctors have stressed the importance of COVID-19 vaccinations, there are also coronavirus treatments helping sick patients stay out of the hospital. Monoclonal antibody therapy is gaining ...

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole while a clear bag slowly empties into a vein. A new generation of ...

From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

If you’re older than 12 and test positive for COVID-19, you most likely qualify to receive monoclonal antibody treatment on Texas’ dime. For most, the largest barrier to getting the early-stage ...

Gazyva (obinutuzumab) is a lab-made antibody medication used for treating certain blood cancers. The FDA recently approved the combined use of Gazyva and standard therapy in adults having an active ...

The dominance of the Delta strain of COVID-19 combined with Alabama’s low vaccination rate has led experts to turn to monoclonal antibody infusion, a treatment in which infected individuals are ...

(Reuters Health) - People living with HIV might someday be able to combat the virus with twice-a-year infusions of anti-HIV antibodies instead of daily antiretroviral pills, two preliminary ...

DALLAS--(BUSINESS WIRE)--Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease. The nationally ...